Pathfinder Cell Therapy, Inc. (PFND)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2014 | -1.66 Million USD | 7.84% |
| 2013 | -1.81 Million USD | 19.58% |
| 2012 | -2.25 Million USD | 88.1% |
| 2011 | -18.92 Million USD | -811.46% |
| 2010 | -2.07 Million USD | 49.4% |
| 2009 | -4.1 Million USD | 6.83% |
| 2008 | -4.4 Million USD | 4.74% |
| 2007 | -4.62 Million USD | -18.69% |
| 2006 | -3.89 Million USD | -81.33% |
| 2005 | -2.14 Million USD | -16.68% |
| 2004 | -1.84 Million USD | -16.74% |
| 2003 | -1.57 Million USD | -50.48% |
| 2002 | -1.04 Million USD | -43.96% |
| 2001 | -728 Thousand USD | -40.0% |
| 2000 | -520 Thousand USD | 45.55% |
| 1999 | -955 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2015 Q2 | -300 Thousand USD | 13.79% |
| 2015 Q1 | -348 Thousand USD | 5.43% |
| 2015 Q3 | -369 Thousand USD | -23.0% |
| 2014 Q3 | -355 Thousand USD | -6.93% |
| 2014 FY | -1.66 Million USD | 7.84% |
| 2014 Q2 | -332 Thousand USD | 31.55% |
| 2014 Q4 | -368 Thousand USD | -3.66% |
| 2014 Q1 | -485 Thousand USD | -4.98% |
| 2013 Q3 | -372 Thousand USD | -28.28% |
| 2013 Q4 | -462 Thousand USD | -24.19% |
| 2013 Q1 | -581 Thousand USD | -12.38% |
| 2013 Q2 | -290 Thousand USD | 50.09% |
| 2013 FY | -1.81 Million USD | 19.58% |
| 2012 Q2 | -634 Thousand USD | -13.82% |
| 2012 Q4 | -517 Thousand USD | -15.4% |
| 2012 FY | -2.25 Million USD | 88.1% |
| 2012 Q1 | -557 Thousand USD | -27.46% |
| 2012 Q3 | -448 Thousand USD | 29.34% |
| 2011 Q3 | -9.07 Million USD | -3027.59% |
| 2011 Q2 | -290 Thousand USD | 31.12% |
| 2011 Q1 | -421 Thousand USD | 13.73% |
| 2011 FY | -18.92 Million USD | -811.46% |
| 2011 Q4 | -437 Thousand USD | 95.18% |
| 2010 Q3 | -599 Thousand USD | 0.17% |
| 2010 Q1 | -389 Thousand USD | 55.03% |
| 2010 Q2 | -600 Thousand USD | -54.24% |
| 2010 Q4 | -488 Thousand USD | 18.53% |
| 2010 FY | -2.07 Million USD | 49.4% |
| 2009 Q1 | -987 Thousand USD | -12.41% |
| 2009 Q3 | -1.07 Million USD | 8.75% |
| 2009 FY | -4.1 Million USD | 6.83% |
| 2009 Q4 | -865 Thousand USD | 19.46% |
| 2009 Q2 | -1.17 Million USD | -19.25% |
| 2008 Q1 | -1.47 Million USD | -198.99% |
| 2008 Q4 | -878 Thousand USD | 15.33% |
| 2008 FY | -4.4 Million USD | 4.74% |
| 2008 Q3 | -1.03 Million USD | -2.37% |
| 2008 Q2 | -1.01 Million USD | 31.42% |
| 2007 Q4 | -494 Thousand USD | 62.17% |
| 2007 FY | -4.62 Million USD | -18.69% |
| 2007 Q1 | -1.14 Million USD | -176.27% |
| 2007 Q2 | -1.68 Million USD | -47.59% |
| 2007 Q3 | -1.3 Million USD | 22.45% |
| 2006 Q3 | -750 Thousand USD | 57.65% |
| 2006 Q4 | -413 Thousand USD | 44.93% |
| 2006 FY | -3.89 Million USD | -81.33% |
| 2006 Q2 | -1.77 Million USD | -84.29% |
| 2006 Q1 | -961 Thousand USD | -197.52% |
| 2005 Q2 | -633 Thousand USD | -23.15% |
| 2005 Q3 | -678 Thousand USD | -7.11% |
| 2005 Q4 | -323 Thousand USD | 52.36% |
| 2005 Q1 | -514 Thousand USD | -153.2% |
| 2005 FY | -2.14 Million USD | -16.68% |
| 2004 Q4 | -203 Thousand USD | 31.65% |
| 2004 Q2 | -586 Thousand USD | 22.38% |
| 2004 Q1 | -755 Thousand USD | -2896.3% |
| 2004 FY | -1.84 Million USD | -16.74% |
| 2004 Q3 | -297 Thousand USD | 49.32% |
| 2003 Q1 | -577 Thousand USD | -23.55% |
| 2003 FY | -1.57 Million USD | -50.48% |
| 2003 Q4 | 27 Thousand USD | 109.71% |
| 2003 Q3 | -278 Thousand USD | 62.88% |
| 2003 Q2 | -749 Thousand USD | -29.81% |
| 2002 Q1 | -217 Thousand USD | -800.0% |
| 2002 FY | -1.04 Million USD | -43.96% |
| 2002 Q2 | -187 Thousand USD | 13.82% |
| 2002 Q4 | -467 Thousand USD | -163.84% |
| 2002 Q3 | -177 Thousand USD | 5.35% |
| 2001 Q4 | 31 Thousand USD | 128.44% |
| 2001 Q3 | -109 Thousand USD | 66.15% |
| 2001 Q2 | -322 Thousand USD | 1.83% |
| 2001 Q1 | -328 Thousand USD | -252.56% |
| 2001 FY | -728 Thousand USD | -40.0% |
| 2000 Q4 | 215 Thousand USD | 252.48% |
| 2000 Q1 | -305 Thousand USD | 0.0% |
| 2000 Q3 | -141 Thousand USD | 51.38% |
| 2000 Q2 | -290 Thousand USD | 4.92% |
| 2000 FY | -520 Thousand USD | 45.55% |
| 1999 FY | -955 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -24.978% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 76.099% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 103.15% |
| Nascent Biotech, Inc. | -2.08 Million USD | 20.055% |
| Rebus Holdings, Inc. | -1.02 Million USD | -63.627% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.562% |
| Qrons Inc. | -789.34 Thousand USD | -111.441% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -163.912% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.334% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -301.705% |
| Skye Bioscience, Inc. | -37.64 Million USD | 95.566% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 97.774% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 74.62% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -510.456% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.9% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 42.297% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 8.323% |
| Mesoblast Limited | -87.95 Million USD | 98.102% |
| Marizyme, Inc. | -65.34 Million USD | 97.446% |
| Genus plc | 7.9 Million USD | 121.127% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 84.676% |
| Pharming Group N.V. | -10.54 Million USD | 84.177% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 23.081% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 55.016% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 81.128% |
| ContraFect Corporation | -65.15 Million USD | 97.438% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 65.842% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 3.384% |
| IMV Inc. | -36.48 Million USD | 95.426% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 79.292% |
| MultiCell Technologies, Inc. | -380.07 USD | -439029.634% |
| ONE Bio Corp. | 8.67 Million USD | 119.236% |
| Accustem Sciences Inc. | -3.74 Million USD | 55.451% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 96.771% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -31.715% |
| Q BioMed Inc. | -2.05 Million USD | 18.668% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 55.291% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 29.9% |
| Biomind Labs Inc. | -1.21 Million USD | -37.443% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.206% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 46.192% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 78.882% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 14.377% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -11044.498% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 89.484% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 71.309% |
| GB Sciences, Inc. | -1.36 Million USD | -22.569% |
| Alpha Cognition Inc. | -13.77 Million USD | 87.882% |
| HST Global, Inc. | -146.21 Thousand USD | -1041.509% |
| CSL Limited | 2.64 Billion USD | 100.063% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 4.888% |
| Halberd Corporation | -79.67 Thousand USD | -1994.734% |
| Enzolytics Inc. | -2.17 Million USD | 23.329% |
| Agentix Corp. | -1.37 Million USD | -21.452% |
| Resverlogix Corp. | -3.61 Million USD | 53.767% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 47.374% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.434% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1803.061% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 124.102% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 57.991% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 44.847% |
| AVAX Technologies, Inc. | -6.41 Million USD | 73.977% |
| Zenith Capital Corp. | -10.59 Million USD | 84.249% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.252% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -7080.965% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 59.744% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2661.388% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 16.763% |
| Kadimastem Ltd | -3.3 Million USD | 49.537% |
| Helix BioMedix, Inc. | -1.05 Million USD | -58.041% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 56.297% |
| BioStem Technologies, Inc. | -8.48 Million USD | 80.325% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -278.142% |
| LadRx Corporation | 400.44 Thousand USD | 516.788% |
| Cell Source, Inc. | -5.32 Million USD | 68.635% |
| Regen BioPharma, Inc. | 1.02 Million USD | 263.067% |
| Regen BioPharma, Inc. | 1.02 Million USD | 263.067% |
| NovAccess Global Inc. | -4.76 Million USD | 65.005% |
| Affymax, Inc. | -14.42 Million USD | 88.429% |
| Itoco Inc. | -1.86 Million USD | 10.701% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 62.431% |
| Mobile Lads Corp. | -2.26 Million USD | 26.258% |
| CytoDyn Inc. | -49.84 Million USD | 96.651% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2011.776% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -631.61% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -77.265% |
| SYBLEU INC | -180.3 Thousand USD | -825.659% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -3.489% |
| International Stem Cell Corporation | -131 Thousand USD | -1174.046% |
| Bioxytran, Inc. | -4.28 Million USD | 61.005% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2975.251% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 34.038% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 96.528% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 21.05% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -113.731% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 47.317% |
| Neutra Corp. | -233.46 Thousand USD | -614.882% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 91.775% |
| PureTech Health plc | -65.69 Million USD | 97.46% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 92.152% |
| IXICO plc | -1.17 Million USD | -41.681% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 83.187% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.078% |
| CSL Limited | 2.64 Billion USD | 100.063% |
| Cellectis S.A. | -103.17 Million USD | 98.382% |